Guardant Health Launches Liquid Biopsy Test For Detecting Colorectal Cancer Recurrence

Guardant wants to become “one-stop-shop” in the cancer care continuum with the launch of an early-stage colorectal cancer test and planned launch of a tissue-based test.

Liquid biopsy

Guardant Health’s CEO Helmy Eltoukhy expects the launch of the company’s new liquid biopsy test, indicated for detecting early-stage colorectal cancer, will be a “big game changer.” 

The new liquid biopsy test, Guardant Reveal, is a plasma-only circulating tumor DNA (ctDNA) test indicated for detecting residual and...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from R&D

More from Business